UNIVERSITY OF UTAH
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1850-02-28
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.utah.edu
Clinical Trials
919
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (708 trials with phase data)• Click on a phase to view related trials
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
- Conditions
- Breast Cancer FemaleGynecologic Cancer
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 19
- Registration Number
- NCT07120100
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
The Impact of Intraoperative Methadone on Postoperative Opioid Use
- Conditions
- Breast CancerOpioid Use
- Interventions
- Drug: Methadon
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 200
- Registration Number
- NCT07092475
- Locations
- 🇺🇸
Joy Ha, Salt Lake City, Utah, United States
Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 30
- Registration Number
- NCT07093177
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty
- Conditions
- Glaucoma, Open AngleMIGSMinimally Invasive Glaucoma SurgeryCanaloplastyIntraocular Pressure (IOP)Cataract SurgerySurgical TechniqueMinimally Invasive Surgical TechniqueGlaucoma
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 100
- Registration Number
- NCT07073937
- Locations
- 🇺🇸
University of Utah John A. Moran Eye Center, Salt Lake City, Utah, United States
UG3 Pilot Clinical Trial
- Conditions
- Lung Cancer
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 65
- Registration Number
- NCT07073898
- Locations
- 🇺🇸
Huntsman Cancer Institute/ University of Utah, Salt Lake City, Utah, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 184
- Next
News
New Research Reveals Complex Effects of Ozempic on Muscle Mass and Strength
Clinical trials demonstrate that GLP-1 agonist drugs like semaglutide (Ozempic) can lead to a 13.9% loss of lean muscle mass, equivalent to approximately 20 years of age-related muscle decline.
Breakthrough: First Successful Stem Cell Transplant Using Deceased Donor for Blood Cancer Treatment
Huntsman Cancer Institute at the University of Utah has achieved the first-ever allogeneic stem cell transplant using cells from a deceased donor, potentially revolutionizing treatment access for blood cancer patients.
Air Pollution During Pregnancy Linked to Severe Neonatal Health Risks and Brain Development Issues
Exposure to air pollution during pregnancy, particularly in the final month, increases newborn risk of requiring intensive care treatment by up to 35%, according to recent research published in Scientific Reports.
Phase III Trial Shows Hypofractionated Radiation Therapy Safe and Effective for Breast Cancer Patients with Reconstruction
The RT CHARM phase III trial demonstrated that shortened radiation therapy (3 weeks) is noninferior to conventional 5-week treatment for breast cancer patients undergoing reconstruction after mastectomy.
Weight Loss Drugs Wegovy and Zepbound Not Cost-Effective at Current Prices, Study Finds
Popular weight loss medications semaglutide (Wegovy) and tirzepatide (Zepbound) would need significant price reductions of 82% and 30% respectively to meet standard cost-effectiveness thresholds, according to new University of Chicago research.
Cooling Therapy Shows No Benefit for Preterm Infants with Brain Injury, NIH Study Finds
A large NIH-funded clinical trial reveals that therapeutic hypothermia, previously successful in term infants, offers no protection against death or disability in preterm infants with hypoxic ischemic encephalopathy.
Higher-Dose, Two-Session Vaginal Brachytherapy Proves Effective for Endometrial Cancer Treatment
A randomized clinical trial led by Huntsman Cancer Institute demonstrates that two sessions of high-dose vaginal brachytherapy are as effective as standard multiple low-dose treatments for endometrial cancer.